Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Hetherington, Kristina L
Lazarus, Jeffrey V
MetadataShow full item record
CitationPolicy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. 2018, 13 (1):e0190146 PLoS ONE
ÚtdrátturIn the Nordic countries (Denmark, Finland, Iceland, Norway, Sweden), the prevalence of chronic hepatitis C virus (HCV) infection is relatively low in the general population, but is much higher among people who inject drugs (PWID). We conducted an exploratory study to investigate the extent to which these countries have policies supporting key elements of the public health response that is necessary to achieve the global goal of eliminating HCV as a public health threat.
Fourteen stakeholders representing government agencies, medical societies, and civil society organisations (CSOs) in the Nordic countries completed a cross-sectional online survey that included 21 policy questions related to national coordination, prevention, testing, linkage to care, and treatment. We summarised the findings in a descriptive analysis, and noted discrepant responses from stakeholders within the same country.
Stakeholders reported that three of the five study countries have national viral hepatitis strategies, while only Iceland has a national HCV elimination goal. The availability of harm reduction services varies, with opioid substitution therapy provided for the general population throughout all countries, but not needle and syringe programmes. No country has access to anonymous HCV testing in all parts of the country. National HCV treatment guidelines are available in all countries except Finland, and all countries provide publicly funded direct-acting antiviral treatment. Disagreement regarding policies was observed across countries, and CSOs were the stakeholder group that most frequently answered survey questions incorrectly.
The Nordic region as a whole has not consistently expressed its commitment to tackling HCV, despite the existence of large HCV epidemics among PWID in these countries. Stakeholder alignment and an established elimination goal with an accompanying strategy and implementation plan should be recognised as the basis for coordinated national public health efforts to achieve HCV elimination in the Nordic region and elsewhere.
Lu00FDsingTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files
RightsArchived with thanks to PloS one
- Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?
- Authors: Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB
- Issue date: 2017 Jul 28
- Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
- Authors: Scott N, Ólafsson S, Gottfreðsson M, Tyrfingsson T, Rúnarsdóttir V, Hansdottir I, Hernandez UB, Sigmundsdóttir G, Hellard M
- Issue date: 2018 May
- Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries.
- Authors: Maticic M, Zorman JV, Gregorcic S, Schatz E, Lazarus JV
- Issue date: 2019 May 9
- Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.
- Authors: Maticic M, Videcnik Zorman J, Gregorcic S, Schatz E, Lazarus JV
- Issue date: 2014
- Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries.
- Authors: Bielen R, Stumo SR, Halford R, Werling K, Reic T, Stöver H, Robaeys G, Lazarus JV
- Issue date: 2018 May 11